ストックスクリーナーアプリを入手
1.72
1.15%
-0.02
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK
Objective long/short (FBIOP) Report - Stock Traders Daily
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com
Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World
FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com
(FBIOP) Trading Signals - Stock Traders Daily
Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com
Certain Restricted Stock Units of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewswire
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):